The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Ironwood Pharmaceuticals, Inc. is $5.35, about 28.9% above its August 5 closing price of $4.15
The stock recently traded at 3 times the next 12-month earnings vs. a P/E of 3 three months ago
IRWD•
